HomeCompareGNHAY vs ABBV

GNHAY vs ABBV: Dividend Comparison 2026

GNHAY yields 5.29% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNHAY wins by $6.14M in total portfolio value
10 years
GNHAY
GNHAY
● Live price
5.29%
Share price
$38.39
Annual div
$2.03
5Y div CAGR
62.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.25M
Annual income
$4,849,407.89
Full GNHAY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GNHAY vs ABBV

📍 GNHAY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNHAYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNHAY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNHAY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNHAY
Annual income on $10K today (after 15% tax)
$449.27/yr
After 10yr DRIP, annual income (after tax)
$4,121,996.71/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GNHAY beats the other by $4,100,940.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNHAY + ABBV for your $10,000?

GNHAY: 50%ABBV: 50%
100% ABBV50/50100% GNHAY
Portfolio after 10yr
$3.17M
Annual income
$2,437,089.83/yr
Blended yield
76.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GNHAY
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNHAY buys
0
ABBV buys
0
No recent congressional trades found for GNHAY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNHAYABBV
Forward yield5.29%3.06%
Annual dividend / share$2.03$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR62.6%40.6%
Portfolio after 10y$6.25M$102.3K
Annual income after 10y$4,849,407.89$24,771.77
Total dividends collected$6.10M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GNHAY vs ABBV ($10,000, DRIP)

YearGNHAY PortfolioGNHAY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,559$859.42$11,550$430.00+$9.00GNHAY
2$13,878$1,509.66$13,472$627.96+$406.00GNHAY
3$17,604$2,754.33$15,906$926.08+$1.7KGNHAY
4$24,146$5,309.21$19,071$1,382.55+$5.1KGNHAY
5$36,902$11,066.02$23,302$2,095.81+$13.6KGNHAY
6$65,185$25,700.29$29,150$3,237.93+$36.0KGNHAY
7$138,737$68,988.48$37,536$5,121.41+$101.2KGNHAY
8$371,577$223,128.79$50,079$8,338.38+$321.5KGNHAY
9$1,305,722$908,134.35$69,753$14,065.80+$1.24MGNHAY
10$6,246,530$4,849,407.89$102,337$24,771.77+$6.14MGNHAY

GNHAY vs ABBV: Complete Analysis 2026

GNHAYStock

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of March 22, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.

Full GNHAY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GNHAY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNHAY vs SCHDGNHAY vs JEPIGNHAY vs OGNHAY vs KOGNHAY vs MAINGNHAY vs JNJGNHAY vs MRKGNHAY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.